Radiopharm Theranostics Limited
RAD
Rank in Stocks
#29858
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Share Price
$0.00276876
Last synced: 2026-11-10
Market Cap
$6.55M
Change (1 day)
0.00%
Change (1 year)
-80.73%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Radiopharm Theranostics Limited (RAD)
Category
Healthcare
EPS for Radiopharm Theranostics Limited (RAD)
EPS as of June 2026 TTM: $-0.01
According to Radiopharm Theranostics Limited's latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.01, an increase over its 2024 EPS of $-0.08.
EPS history for Radiopharm Theranostics Limited from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | 10.00% |
| 2025 | $-0.01 | -85.52% |
| 2024 | $-0.08 | 9.28% |
| 2023 | $-0.07 | -3.43% |
| 2022 | $-0.08 | 5,738.46% |
| 2021 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -142,463.64% |
US
|
|
| $-7.07 | 64,172.73% |
US
|
|
| $-5.29 | 47,990.91% |
AU
|
|
| $12.88 | -117,191.82% |
BE
|
|
| $21.56 | -196,100.00% |
NL
|
Questions about Radiopharm Theranostics Limited's earnings per share (EPS)
What is Radiopharm Theranostics Limited's earnings per share (EPS)?
Radiopharm Theranostics Limited's earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was Radiopharm Theranostics Limited's earnings per share (EPS) in 2025?
In 2025, Radiopharm Theranostics Limited's earnings per share (EPS) was $-0.01, compared with $-0.08 in 2024.
How has Radiopharm Theranostics Limited's earnings per share (EPS) changed since 2021?
From 2021 to 2025, Radiopharm Theranostics Limited's earnings per share (EPS) was highest in 2021 (0.00) and lowest in 2024 ($-0.08).
How does Radiopharm Theranostics Limited's earnings per share (EPS) compare with similar companies?
Radiopharm Theranostics Limited's earnings per share (EPS) ($-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.